New drug duo takes on Hard-to-Treat cancers
NCT ID NCT05765851
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called DS-1103a combined with an existing cancer drug, Enhertu, in people with advanced solid tumors that have a specific genetic marker (HER2). The study aims to find a safe dose and see if the combination shrinks tumors. About 108 adults with advanced or metastatic cancer are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DS-1103a combined with trastuzumab deruxtecan (T-DXd, Enhertu)
What this could lead to
If successful, this could point toward a new combination treatment for advanced solid tumors that have HER2 mutations or overexpression.
What could go wrong
This is a very early Phase 1 trial with only 108 participants, so safety and dosing are still being figured out. Many early-stage cancer trials do not lead to approved treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
ACTIVE_NOT_RECRUITINGLyon, Rhone, 69373, France
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
Hospital Universitari Vall d'Hebron
ACTIVE_NOT_RECRUITINGBarcelona, 8035, Spain
-
Lifespan Cancer Institute
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Oncopole - Institut Claudius Regaud
ACTIVE_NOT_RECRUITINGToulouse, Haute Garonne, 31059, France
-
Princess Margaret Cancer Centre, University Health Network
ACTIVE_NOT_RECRUITINGToronto, M5G 2M9, Canada
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact